Page last updated: 2024-11-06

4-ipomeanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-ipomeanol: lung-toxic furanoterpenoid produced in moldy sweet potatoes in response to fungus infection; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36284
CHEMBL ID1743358
CHEBI ID173764
SCHEMBL ID61911
MeSH IDM0041681

Synonyms (39)

Synonym
CHEBI:173764
1-(uran-3-yl)-4-hydroxypentan-1-one
NCI60_003112
4-ipomeanol
32954-58-8
1-pentanone, 1-(3-furanyl)-4-hydroxy-
NSC349438 ,
nsc-349438
1-(beta-furyl)-4-hydroxypentanone
1-pentanone, 1-(3-furyl)-4-hydroxy-
1-(3-furyl)-4-hydroxy-1-pentanone
hsdb 3498
pentanone, 1-(3-furyl)-4-hydroxy-
ccris 705
1-(3-furyl)-4-hydroxypentanone
ipomeanol
1-(3-furyl)-4-hydroxy-4-pentanone
1-(3-furyl)-4-hydroxy-pentan-1-one
55659-41-1
nsc 644432
1-(furan-3-yl)-4-hydroxypentan-1-one
CHEMBL1743358 ,
AKOS006279860
nsc 644433
nsc 349438
bdbm50418090
SCHEMBL61911
1-(3-furyl)-4-hydroxy-1-pentanone #
RJYQLMILDVERHH-UHFFFAOYSA-N
1-pentanone, 1-(3-furanyl)-4-hydroxy-, (+/-)-
36878-93-0
URT1FLO407 ,
(+/-)-4-ipomeanol
unii-urt1flo407
1-(3-furanyl)-4-hydroxy-1-pentanone, 9ci
3-(4-hydroxypentanoyl)furan
Q27291230
DTXSID10866492
PD011914

Research Excerpts

Toxicity

4-Ipomeanol (IPO) is a prototypical pulmonary toxin that requires P450-mediated metabolic activation to reactive intermediates in order to elicit its toxic effects. Studies with inducers of the hepatic metabolism of 4-ipomeanol are consistent with the view that the toxic metabolite of the compound is actually formed in situ in the target tissue.

ExcerptReferenceRelevance
" Studies with inducers of the hepatic metabolism of 4-ipomeanol are consistent with the view that the toxic metabolite of the compound is actually formed in situ in the target tissue."( In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol.
Boyd, MR; Burka, LT, 1978
)
0.71
"The lungs may be exposed to potentially toxic metabolites that are either formed in situ or which are present in the circulation."( Metabolic activation and lung toxicity: a basis for cell-selective pulmonary damage by foreign chemicals.
Boyd, MR, 1984
)
0.27
"When a compound that is removed from the body by metabolism produces toxicity in extrahepatic organs directly, rather than via active metabolites, induction or inhibition of the drug-metabolizing enzymes simply will decrease or enhance, respectively, the toxic effects of the compound."( Effects of inducers and inhibitors on drug-metabolizing enzymes and on drug toxicity in extrahepatic tissues.
Boyd, MR, 1980
)
0.26
" Pulmonary concentrations of unmetabolized 4-ipomeanol were decreased by MC through an increased metabolism of 4-ipomeanol in the liver, primarily to toxic products that bind covalently in that tissue and lead to hepatoxicity."( Effects of phenobarbital and 3-methylcholanthrene on the in vivo distribution, metabolism and covalent binding of 4-ipomeanol in the rat; implications for target organ toxicity.
Boyd, MR; Statham, CN, 1982
)
0.74
"25 of the LD50 for adults) killed 6 of 10 neonatal rabbits."( Elevated susceptibility to 4-ipomeanol cytotoxicity in immature Clara cells of neonatal rabbits.
Buckpitt, AR; Chang, A; Nishio, SJ; Philpot, RM; Plopper, CG; Voit, M; Weir, AJ, 1994
)
0.59
" Toxic effects were also noted in other tissues capable of activating IPO, including possible nephrotoxicity in a patient treated with one course of IPO at 154 mg/m2 and severe, reversible pulmonary toxicity in another patient who received nine courses of IPO at doses ranging from 202 to 826 mg/m2."( Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Boyd, MR; Christian, MC; Donehower, RC; Ettinger, DS; Fishman, EK; Lubejko, BG; Noe, DA; Rowinsky, EK; Sartorius, SE, 1993
)
0.53
"4-Ipomeanol (IPO) is a prototypical pulmonary toxin that requires P450-mediated metabolic activation to reactive intermediates in order to elicit its toxic effects."( Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol.
Kelly, EJ; Liggitt, HD; Parkinson, OT; Rettie, AE, 2013
)
1.83

Compound-Compound Interactions

ExcerptReferenceRelevance
" The U3 region of the myeloproliferative sarcoma virus in combination with the T2A site was found to drive high-level expression of our CYP4B1 mutant with truncated CD34 or CD271 as MACS suitable selection markers."( Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.
Altvater, B; Edson, KZ; Einholz, R; Hanenberg, H; Kramm, CM; Reinhardt, D; Rettie, AE; Roellecke, K; Rossig, C; Scheckenbach, K; Virts, EL; von Laer, D; Wagenmann, M; Wiek, C, 2016
)
0.67

Dosage Studied

ExcerptRelevanceReference
" Time-course and dose-response studies demonstrate a close correlation between the pulmonary alkylation and the lung toxicity of the compound."( In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol.
Boyd, MR; Burka, LT, 1978
)
0.46
" Labored respiration, terminal bronchiolar epithelial necrosis, interstitial inflammation, and alveolar edema were present in rats dosed with ipomeanol at greater than or equal to 9 mg/kg."( Preclinical toxicology studies of 4-ipomeanol: a novel candidate for clinical evaluation in lung cancer.
Barrett, D; Boyd, MR; el-Hawari, M; Grieshaber, CK; Kastello, MD; Smith, AC; Stedham, MA, 1987
)
0.55
"Inhibition of pulmonary CYP4B1 activity by pretreatment of rats with p-xylene decreased the ability of lung microsomes to N-hydroxylate 2-aminofluorene and prevented the lung damage normally seen after dosing with ipomeanol."( CYP4B1 activates 4-ipomeanol in rat lung.
Dinsdale, D; Philpot, RM; Verschoyle, RD; Wolf, CR, 1993
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Ki20.00000.00011.41629.9000AID589120
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID589120Mechanism based inhibition of human cytochrome P450 3A4 measured by DBF fluorescence2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID589192Mechanism based inhibition of human cytochrome P450 3A4, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (90)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (46.67)18.7374
1990's27 (30.00)18.2507
2000's11 (12.22)29.6817
2010's10 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.44 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index33.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (4.17%)5.53%
Reviews14 (14.58%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other78 (81.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]